A commercial alpha-amylase inhibitor with potent inhibitory activity in vitro was used in a randomized double-blind, cross-over clinical trial in six nonobese, healthy adult males. In these subjects, this inhibitor had no effect on the response of blood glucose, insulin, or breath hydrogen to a standardized starch meal. It is concluded that this formulation has no effect on starch digestion in humans.
No takes yet. Share an insight, caveat, or question.
Carlson et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: